An Exploratory Open-Label Phase 2 Study of EPI-743 (Vincerinone) in Children With Autism Spectrum Disorder
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2015
At a glance
- Drugs Vatiquinone (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors Edison Pharmaceuticals
- 09 Mar 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 07 Oct 2014 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
- 07 Oct 2014 Planned primary completion date changed from 1 Oct 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.